Unlocking Trillion-Dollar Value: Investing in Cardiac AI’s Future

AI in preventive cardiology is supposed to be about stopping heart attacks, not just treating them after the fact. For an investor, though, the space is a mess of companies all claiming to be the future. To find the real winners, you need to ignore the marketing hype and look for hard numbers. The only thing that matters is proof the tech works in the clinic and actually improves patient outcomes. Anything else is just noise.

The Imperative of Proactive Risk Mitigation in Cardiovascular AI

The whole point of using AI in healthcare is to get ahead of problems. For cardiology, that means finding the person who’s on track for a heart attack before they feel any chest pain. This isn’t some new idea. The AHA guidelines on preventive cardiology have been screaming about early risk detection for years. So, the best AI platforms are the ones that give doctors insights they can actually act on to lower event rates. Investors get sidetracked by FDA clearances, but a 510(k) often just means a device is similar to something that’s already out there, it’s a check-the-box exercise. Real value comes from a company’s “data moat,” the unique, high-quality data they use to train their algorithms, and from securing Category I CPT codes, which proves doctors can actually get paid for using the tech. Without reimbursement, there’s no business.

Benchmarking Leading Platforms: Precision, Prediction, and Adherence

So, which AI platforms are actually leading the charge in preventive cardiology? To answer that, you have to measure them with real-world metrics like their preventive intervention efficacy rates (how well do their recommendations actually stop heart attacks?), risk prediction accuracy, and patient adherence. Let’s look at three companies, Cleerly, Cardioscan, and Preventice Solutions, and see how they stack up on actual prevention.

Cleerly: Pioneering Preventive Plaque Analysis

Cleerly’s entire game is about looking at plaque differently. For decades, cardiologists have focused on lumen stenosis, basically how blocked an artery is, but that’s a crude measure that can miss the real danger. Cleerly uses AI to analyze CCTA scans and quantify the plaque itself, its type, volume, and vulnerability. This gives a much clearer picture of the actual disease. The key benchmark for them is simple: can they use these plaque details to spot someone who’s going to have a heart attack, even if their arteries aren’t severely blocked yet? As their peer-reviewed studies show, this kind of quantitative analysis is far better at stratifying risk than old-school scores. The idea is to find that dangerous, vulnerable plaque early so a doctor can hit it hard with statins and lifestyle changes to stop a future myocardial infarction. This is a true “health moonshot” for investors because it’s a fundamental shift in practice. The ultimate proof will be in their preventive intervention efficacy rates, showing that acting on their analysis actually lowers the number of heart attacks. Getting FDA Breakthrough Device Designation for their CAD Staging System was a big step, and securing Medicare coverage with a Category I CPT code starting January 1, 2026, means they have a clear path to getting paid.

Cardioscan: AI-Enhanced ECG Analysis for Early Detection

Cardioscan’s bet is that there are hidden signals in routine ECGs that we’re currently missing. They use AI to comb through electrocardiogram data, looking for tiny patterns that a human eye or a standard algorithm would just skip over. Their AI-native setup means they can process a huge volume of ECGs quickly, theoretically spotting things like atrial fibrillation or hypertrophic cardiomyopathy much earlier. But does it work? For Cardioscan, the benchmark is all about risk prediction accuracy. Can their analysis pick an asymptomatic person out of a crowd and say, “this person is at high risk,” with enough confidence for a doctor to intervene? For an investor, the only question that matters is if their AI delivers a real jump in sensitivity and specificity over a cardiologist just reading the ECG normally. To do that, they need a massive “data moat” of labeled ECGs to keep their models sharp and avoid algorithmic drift over time. And, of course, the tech has to plug into the hospital’s workflow without causing a headache for the staff.

Preventice Solutions (now part of Boston Scientific): Remote Cardiac Monitoring

Preventice Solutions, now part of Boston Scientific since their deal closed on March 1, 2021, is in the remote monitoring business with its BodyGuardian devices. Most people think of these continuous ECG monitors as a tool for patients who are already having symptoms. The preventive angle, however, is its ability to catch fleeting events, like a transient arrhythmia that only appears for a minute in the middle of the night, that would be completely missed in a clinic visit. For someone with known risk factors, that kind of surveillance can catch a problem before it becomes a crisis. The benchmarks here are different. You’re looking at patient adherence percentages (do people actually wear the device?) and the rate of actionable findings in patients who don’t have symptoms yet. Preventice isn’t “predicting” risk like Cleerly, but it is enabling proactive care. The hard part for investors is separating the preventive value from the reactive monitoring. The focus has to be on how many times their data helps a doctor make a call that prevents a hospital stay, not just documents an event that was already happening. For a company handling so much patient data, things like their QMS/ISO 13485 certification and tight HIPAA/HITRUST/SOC 2 compliance are non-negotiable table stakes.

The Investor Takeaway: Prioritize Proactive Risk Mitigation

The bottom line for investors is simple: bet on companies that are genuinely moving the needle on proactive risk management, not just putting a fancier wrapper on reactive care. The real leaders will be the ones who can show you the data proving they can:

• Get better at early risk detection: Finding the at-risk patient before they have symptoms. This is the core pitch for both Cleerly’s plaque analysis and Cardioscan’s predictive ECG insights.
• Prove their interventions work: Showing that when a doctor follows their AI’s recommendation, it actually leads to fewer heart attacks, strokes, or hospital stays.
• Keep patients on board: Making sure the insights lead to a patient actually taking their meds or changing their lifestyle. This is where a company like Preventice, with its monitoring tech, plays a part.

The AI market is going to split along these lines. Companies with “AI-powered” marketing but no peer-reviewed proof of preventive impact are going to end up as “zombie companies.” If you’re chasing a “health moonshot” in cardiology, you need a company with solid clinical evidence, a smart regulatory plan (like going for a De Novo classification if their tech is truly new), and a clear way to get paid, those Category I CPT codes are gold. That means doing real technical diligence on their data moat, their GMLP (Good Machine Learning Practice) implementation, and how they plan to handle algorithmic drift.

Methodology Note on Benchmarks

The benchmarks I’m talking about here come straight from reviewing guidelines from the American College of Cardiology and scientific statements from the American Heart Association. The specific numbers for “preventive intervention efficacy rates” or “risk prediction accuracy metrics” will obviously change depending on whether you’re looking at a 40-year-old with a bad family history or a 70-year-old with diabetes, but the core idea doesn’t change. You’re looking for platforms that can prove, with data, that they are better than the current standard of care at finding and stopping cardiovascular risk before it’s too late. This is the framework you use to separate a minor tweak from a real breakthrough, as laid out in things like the ACC/AHA joint guidelines on cardiovascular disease prevention. We’re trying to find the platforms that actually improve population health by intervening earlier and smarter.